ライフサイエンスコーパス: prostate-specific membrane antigen

1 novel radiolabeled small molecules targeting prostate-specific membrane antigen.

2 specificity for the extracellular domain of prostate-specific membrane antigen.

3 investigated whether and how (68)Ga-labeled prostate-specific membrane antigen 11 ((68)Ga-PSMA-11) P

4 luate the feasibility of rechallenge (177)Lu-prostate-specific membrane antigen ((177)Lu-PSMA) radiol

5 e of early PSA changes after (177)Lu-labeled prostate-specific membrane antigen ((177)Lu-PSMA) radion

6 an serve as a response predictor for (177)Lu-prostate-specific membrane antigen 617 (PSMA) radioligan

7 in recipients of (177)Lu-DOTATOC or (177)Lu-prostate specific membrane antigen-617 (PSMA) radioligan

8 A limitation of using (68)Ga-labeled prostate-specific membrane antigen ((68)Ga-PSMA) for det

9 PET using (68)Ga prostate-specific membrane antigen ((68)Ga-PSMA) is a pr

10 his study was to assess the impact of (68)Ga-prostate-specific membrane antigen ((68)Ga-PSMA) PET/CT

11 heses, or pedicle screws) and (68)Ga-labeled prostate-specific membrane antigen ((68)Ga-PSMA) PET/CT

12 (68)Ga-labeled prostate-specific membrane antigen ((68)Ga-PSMA) PET/CT

13 investigate if the new tracer targeting the prostate-specific membrane antigen ((68)Ga-PSMA-11) coul

14 ents receiving (18)F-fluciclovine and (68)Ga-prostate-specific membrane antigen ((68)Ga-PSMA-11) for

15 onjugates with RNA aptamers that bind to the prostate-specific membrane antigen, a well-known prostat

16 Until prostate-specific membrane antigen agents are fully appr

17 cancer, antibodies to key antigens, such as prostate specific membrane antigen, along with metabolic

18 tate cancer (SyAM-Ps)-bind simultaneously to prostate-specific membrane antigen and Fc gamma receptor

19 )In-DOTAGA-(3-iodo-y)-f-k-Sub(KuE)) (PSMA is prostate-specific membrane antigen and I&T is imaging an

20 ing RLT with (177)Lu-DOTATATE, -DOTATOC, or -prostate-specific membrane antigen and showing laborator

21 acetic acid octreotate (or DOTATATE), (68)Ga prostate-specific membrane antigen, and (18)F-fluciclovi

22 es that target prostate-specific antigen and prostate-specific membrane antigen, and drugs that can b

23 against tumor-associated antigens, including prostate-specific membrane antigen, and elimination of p

24 vesicles displaying an aptamer that binds to prostate-specific membrane antigen, and loaded with surv

25 an spectroscopy, exogenous fluoroscopy using prostate-specific membrane antigen, and so on have led t

26 nal antibodies, antibody therapies targeting prostate-specific membrane antigen, and vaccines such as

27 PET and monoclonal antibody imaging with the prostate specific membrane antigen antibody (111)In-capr

28 An anti-prostate specific membrane antigen aptamer that has prev

29 Synchronous (68)Ga-labeled prostate-specific membrane antigen-avid malignancies wer

30 Here, we use a series of prostate-specific membrane antigen-binding single-domain

31 ke therapeutics in which a derivative of the prostate-specific membrane antigen-binding small molecul

32 those directed to glucose, choline, acetate, prostate-specific membrane antigen, bombesin, and amino

33 KLK3 (prostate-specific antigen ) and FOLH1 (prostate-specific membrane antigen) but not in AR and KL

34 ion dependent upon T-cell recognition of the prostate-specific membrane antigen by a chimeric antigen

35 treatment of advanced prostate cancer using prostate-specific membrane antigen-directed radionuclide

36 d to assessment of (177)Lu-PSMA-617 therapy (Prostate-Specific Membrane Antigen) for metastatic prost

37 from the prostate-specific antigen (PSA) and prostate-specific membrane antigen gene regulatory regio

38 body that targets the external domain of the prostate-specific membrane antigen, has potential as an

39 Important PCa radiotracers include (68)Ga-prostate-specific membrane antigen HBED-CC ((68)Ga-PSMA)

40 The PET radiotracer (68)Ga-PSMA (prostate-specific membrane antigen)-HBED-CC (N,N'-bis [2

41 state carcinoma tumors transduced with human prostate-specific membrane antigen (hPSMA) and a Renilla

42 dioimmunoscintigraphy (RIS) directed against prostate-specific membrane antigen in modifying postpros

43 3 lowered the kidney and liver uptake of the prostate-specific membrane antigen inhibitor each by a f

44 therapy (RLT) with (177)Lu-PSMA-617 (PSMA is prostate-specific membrane antigen) is a novel targeted

45 ode dissection (SLND) and pre/post procedure prostate-specific membrane antigen ligand positron emiss

46 a-linked acidic dipeptidase 2 (NAALAD2), and prostate-specific membrane antigen-like protein (PMSAL/G

47 esferrioxamine-IAB2M ((89)Zr-IAB2M), an anti-prostate-specific membrane antigen minibody, in patients

48 dose, 180 MBq; range, 126-189 MBq) targeting prostate-specific membrane antigen (n = 7) or human epid

49 Glutamate carboxypeptidase II (GCPII or prostate-specific membrane antigen or NAALADase) is an e

50 Prostate-specific membrane antigen PET agents such as 2-

51 ort (in the context of emerging evidence for prostate-specific membrane antigen PET in this setting)

52 Prostate-specific membrane antigen PET tracers are in th

53 (68)Ga-prostate-specific membrane antigen PET/CT ((68)Ga-PSMA P

54 DOTATOC PET/CT (GEP NET), and (68)Ga-labeled prostate-specific membrane antigen PET/CT (PCA) but is s

55 ancies in patients undergoing (68)Ga-labeled prostate-specific membrane antigen PET/CT for prostate c

56 Ga-68 Prostate-Specific Membrane Antigen PET/CT is a new tool

57 However, localizing BCR with prostate-specific membrane antigen PET/CT remains challe

58 (68)Ga-prostate-specific membrane antigen PET/CT scans of PCa p

59 ncer (BCR) is the main indication to perform prostate-specific membrane antigen PET/CT.

60 68)Ga(HBED-CC)] ((68)Ga-PSMA ligand; PSMA is prostate-specific membrane antigen) PET/CT in patients w

61 (68)Ga-PSMA (prostate-specific membrane antigen) PET/CT is increasing

62 for imaging metastases, whereas (68)Ga-PSMA (prostate-specific membrane antigen) PET/CT was introduce

63 MEDI3726 targets prostate-specific membrane antigen (PMSA) and is compris

64 Prostate-specific membrane antigen (PMSA) is an integral

65 eted RNAi agents that selectively sensitized prostate-specific membrane antigen-positive (PSMA-positi

66 te LNCaP epithelial cells, which express the prostate-specific membrane antigen protein (77-fold incr

67 ot enhanced in cells that do not express the prostate-specific membrane antigen protein.

68 PCR) for prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSM) to predict path

69 r proteins, prostate specific antigen (PSA), prostate specific membrane antigen (PSMA) and platelet f

70 I) microfluidic device that combines an anti-prostate specific membrane antigen (PSMA) antibody with

71 SMA) is a radioligand with high affinity for prostate specific membrane antigen (PSMA) enabling targe

72 For prostate cancer, prostate specific membrane antigen (PSMA) has been ident

73 A series of phosphoramidate-based prostate specific membrane antigen (PSMA) inhibitors of

74 Prostate specific membrane antigen (PSMA) is a membrane-

75 Prostate specific membrane antigen (PSMA) is a validated

76 th small molecular entities, able to bind to prostate specific membrane antigen (PSMA), a transmembra

77 Prostate specific membrane antigen (PSMA), also known as

78 against prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA), and then used

79 egy for the detection of a cancer biomarker, prostate specific membrane antigen (PSMA), at picomolar

80 which target the extracellular domain of the prostate specific membrane antigen (PSMA), for enhanced

81 roteins are prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), platelet fact

82 to measure prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), platelet fact

83 to aptamers that recognize the transmembrane prostate specific membrane antigen (PSMA), with cells se

84 CD30-AshR-negative control chimera and prostate specific membrane antigen (PSMA)-AshR-RORgammat

85 ted for the detection of a tumor marker, the Prostate Specific Membrane Antigen (PSMA).

86 -urea-Lys (Ahx)-HBED-CC ligand targeting the prostate-specific membrane antigen (PSMA) ((68)Ga-PSMA-1

87 -urea-Lys (Ahx)-HBED-CC ligand targeting the prostate-specific membrane antigen (PSMA) (hereafter cal

88 ent in prostate cancer patients using (68)Ga-prostate-specific membrane antigen (PSMA) 11 PET/CT.

89 Promising biochemical responses to (225)Ac-prostate-specific membrane antigen (PSMA) 617, even in p

90 partial-volume correction (PVC) on measured prostate-specific membrane antigen (PSMA) activity in sm

91 and accessibility of (68)Ga tracers for the prostate-specific membrane antigen (PSMA) and other targ

92 Radioactive ligands for the prostate-specific membrane antigen (PSMA) are under deve

93 based low-molecular weight inhibitors of the prostate-specific membrane antigen (PSMA) are under inte

94 algorithms to predict peptide sequences from prostate-specific membrane antigen (PSMA) capable of sti

95 Agents targeting prostate-specific membrane antigen (PSMA) comprise a rap

96 bivalent antibody fragments, including anti-prostate-specific membrane antigen (PSMA) diabody (Db) a

97 for targeted immunoPET and quantification of prostate-specific membrane antigen (PSMA) expression in

98 Based on prostate-specific membrane antigen (PSMA) expression on

99 sferrioxamine B [DFO]-J591 for immuno-PET of prostate-specific membrane antigen (PSMA) expression was

100 ty of (68)Ga-labeled PET tracers against the prostate-specific membrane antigen (PSMA) for localizati

101 ed, (211)At-labeled small molecule targeting prostate-specific membrane antigen (PSMA) for the treatm

102 The prostate-specific membrane antigen (PSMA) has received i

103 ecent years, a number of drugs targeting the prostate-specific membrane antigen (PSMA) have become im

104 recent years, several radioligands targeting prostate-specific membrane antigen (PSMA) have been clin

105 nt years, several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been intr

106 Prostate cancer cells expressing prostate-specific membrane antigen (PSMA) have been targ

107 Small-molecule ligands specific for prostate-specific membrane antigen (PSMA) have the poten

108 range, 0.75-2.55 ng/mL) who underwent (68)Ga-prostate-specific membrane antigen (PSMA) HBED-CC PET/CT

109 sensitive immunoassay for quantitating serum prostate-specific membrane antigen (PSMA) hinders its cl

110 The anti-prostate-specific membrane antigen (PSMA) huJ591 antibod

111 anced prostate cancer and positive uptake in prostate-specific membrane antigen (PSMA) imaging were t

112 Prostate-specific antigen and prostate-specific membrane antigen (PSMA) immunohistoche

113 dioimmunoscintigraphy (RIS) directed against prostate-specific membrane antigen (PSMA) in influencing

114 dioimmunoscintigraphy (RIS) directed against prostate-specific membrane antigen (PSMA) in influencing

115 ns of radioligand therapy (RLT) with (177)Lu-prostate-specific membrane antigen (PSMA) in metastasize

116 sis of the high and consistent expression of prostate-specific membrane antigen (PSMA) in metastatic

117 response to (177)Lu-labeled agents targeting prostate-specific membrane antigen (PSMA) in patients wi

118 Radiolabeling of the prostate-specific membrane antigen (PSMA) inhibitor Glu-

119 ork aimed at the development of dual-labeled prostate-specific membrane antigen (PSMA) inhibitors der

120 In recent years, prostate-specific membrane antigen (PSMA) inhibitors wer

121 Prostate-specific membrane antigen (PSMA) is a carboxype

122 Prostate-specific membrane antigen (PSMA) is a promising

123 Prostate-specific membrane antigen (PSMA) is a promising

124 Prostate-specific membrane antigen (PSMA) is a transmemb

125 Prostate-specific membrane antigen (PSMA) is a transmemb

126 Prostate-specific membrane antigen (PSMA) is a transmemb

127 Prostate-specific membrane antigen (PSMA) is a transmemb

128 Prostate-specific membrane antigen (PSMA) is a type 2 in

129 Prostate-specific membrane antigen (PSMA) is a type II i

130 Prostate-specific membrane antigen (PSMA) is a well-char

131 Prostate-specific membrane antigen (PSMA) is a well-esta

132 Prostate-specific membrane antigen (PSMA) is a well-reco

133 The prostate-specific membrane antigen (PSMA) is an attracti

134 Prostate-specific membrane antigen (PSMA) is an excellen

135 The prostate-specific membrane antigen (PSMA) is an excellen

136 Prostate-specific membrane antigen (PSMA) is expressed i

137 Prostate-specific membrane antigen (PSMA) is highly expr

138 The prostate-specific membrane antigen (PSMA) is highly expr

139 Prostate-specific membrane antigen (PSMA) is highly expr

140 Prostate-specific membrane antigen (PSMA) is highly expr

141 Prostate-specific membrane antigen (PSMA) is highly expr

142 Prostate-specific membrane antigen (PSMA) is highly over

143 The expression of prostate-specific membrane antigen (PSMA) is increased i

144 The prostate-specific membrane antigen (PSMA) is increasingl

145 The prostate-specific membrane antigen (PSMA) is increasingl

146 PET using radiolabeled prostate-specific membrane antigen (PSMA) is now being m

147 Prostate-specific membrane antigen (PSMA) is of consider

148 Because the prostate-specific membrane antigen (PSMA) is overexpress

149 Prostate-specific membrane antigen (PSMA) is overexpress

150 Prostate-specific membrane antigen (PSMA) is overexpress

151 Prostate-specific membrane antigen (PSMA) is overexpress

152 Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising f

153 on previous observations, we first show that prostate-specific membrane antigen (PSMA) is repressed b

154 The transmembrane peptidase prostate-specific membrane antigen (PSMA) is universally

155 Since prostate-specific membrane antigen (PSMA) is up-regulate

156 efficacy of the (177)Lu-labeled DOTAGA-based prostate-specific membrane antigen (PSMA) ligand (177)Lu

157 Prostate-specific membrane antigen (PSMA) ligand PET ind

158 (SLND) and pre-procedure and post-procedure prostate-specific membrane antigen (PSMA) ligand PET.

159 Therefore, we evaluated whether prostate-specific membrane antigen (PSMA) ligand PET/CT

160 lar imaging using PET/CT with (68)Ga-labeled prostate-specific membrane antigen (PSMA) ligands and mo

161 PET combined with CT and prostate-specific membrane antigen (PSMA) ligands has ga

162 Radiolabeled prostate-specific membrane antigen (PSMA) ligands repres

163 Prostate-specific membrane antigen (PSMA) may be targete

164 (68)Ga- and (18)F-labeled prostate-specific membrane antigen (PSMA) molecules have

165 zed with the A10 aptamer, which binds to the prostate-specific membrane antigen (PSMA) on prostate ca

166 nd the A10 aptamer (Apt), which binds to the prostate-specific membrane antigen (PSMA) on the surface

167 Prostate-specific membrane antigen (PSMA) or folate hydr

168 ced molecular imaging techniques, especially prostate-specific membrane antigen (PSMA) PET findings,

169 rrelation of PSA changes with the results of prostate-specific membrane antigen (PSMA) PET follow-up

170 aluated the diagnostic value and accuracy of prostate-specific membrane antigen (PSMA) PET for the in

171 Radiolabeled prostate-specific membrane antigen (PSMA) PET has demons

172 Quantitative evaluation of radiolabeled prostate-specific membrane antigen (PSMA) PET scans may

173 (18)F-labeled prostate-specific membrane antigen (PSMA) PET tracers ar

174 Association of Urology guidelines recommend prostate-specific membrane antigen (PSMA) PET-CT.

175 mine the diagnostic capabilities of combined prostate-specific membrane antigen (PSMA) PET/CT and sen

176 The importance of prostate-specific membrane antigen (PSMA) PET/CT for pri

177 Prostate-specific membrane antigen (PSMA) PET/CT has a h

178 The potential role of prostate-specific membrane antigen (PSMA) PET/CT in non-

179 We thus assessed the value of prostate-specific membrane antigen (PSMA) PET/CT in the

180 (68)Ga-prostate-specific membrane antigen (PSMA) PET/CT is a ne

181 (68)Ga-prostate-specific membrane antigen (PSMA) PET/CT is a pr

182 (68)Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT is incr

183 The impact of prostate-specific membrane antigen (PSMA) PET/CT on mana

184 (68)Ga-prostate-specific membrane antigen (PSMA) PET/CT positiv

185 ancer (PCa) cohort to date undergoing (68)Ga-prostate-specific membrane antigen (PSMA) PET/CT primary

186 (68)Ga-prostate-specific membrane antigen (PSMA) PET/CT scans w

187 Therefore, we evaluated consecutive (68)Ga-prostate-specific membrane antigen (PSMA) PET/CT, (11)C-

188 between fluciclovine and gallium 68 or (18)F prostate-specific membrane antigen (PSMA) PET/CT, a newe

189 Since the introduction of radiolabeled prostate-specific membrane antigen (PSMA) PET/CT, the ab

190 (177)Lu-prostate-specific membrane antigen (PSMA) radioligand th

191 (177)Lu-labeled prostate-specific membrane antigen (PSMA) radioligand th

192 The intense accumulation of prostate-specific membrane antigen (PSMA) radioligands i

193 er cells by constructing Pt(IV)-encapsulated prostate-specific membrane antigen (PSMA) targeted nanop

194 ion detection rate of (18)F-DCFPyL-PET/CT, a prostate-specific membrane antigen (PSMA) targeted PET a

195 rmaceuticals, we developed inhibitors of the prostate-specific membrane antigen (PSMA) that are label

196 e high-affinity urea-based inhibitors of the prostate-specific membrane antigen (PSMA) that were synt

197 highly specific small molecule targeting the prostate-specific membrane antigen (PSMA) to deliver (12

198 (99m)Tc-PSMA I&S is a prostate-specific membrane antigen (PSMA) tracer that ca

199 There is increasing interest in PET/CT with prostate-specific membrane antigen (PSMA) tracers for im

200 Prostate-specific membrane antigen (PSMA) uptake has bee

201 fect of androgen receptor (AR) inhibition on prostate-specific membrane antigen (PSMA) uptake imaged

202 compounds labeled with (86)Y for imaging the prostate-specific membrane antigen (PSMA) using PET.

203 which a bivalent aptamer specifically binds prostate-specific membrane antigen (PSMA) via an antibod

204 The overexpression of the prostate-specific membrane antigen (PSMA) was exploited

205 A phage-derived peptide targeting the prostate-specific membrane antigen (PSMA) was geneticall

206 Targeting the prostate-specific membrane antigen (PSMA) with (68)Ga-la

207 re that these materials are able to (1) bind prostate-specific membrane antigen (PSMA) with high affi

208 nt prostate cancer by radioligands targeting prostate-specific membrane antigen (PSMA), 30% of patien

209 cles selectively bound either an antibody or prostate-specific membrane antigen (PSMA), a biomarker f

210 (177)Lu-PSMA-617 targets prostate-specific membrane antigen (PSMA), a cell-surfac

211 Prostate-specific membrane antigen (PSMA), a glutamyl pr

212 was designed for label-free immunosensing of prostate-specific membrane antigen (PSMA), a prostate ca

213 o PEDOT films for electrochemical sensing of prostate-specific membrane antigen (PSMA), a prostate ca

214 body (mAb) construct for targeted imaging of prostate-specific membrane antigen (PSMA), a prototypica

215 Prostate-specific membrane antigen (PSMA), a transmembra

216 Prostate-specific membrane antigen (PSMA), a type II tra

217 at recognize the extracellular domain of the prostate-specific membrane antigen (PSMA), a well charac

218 n peripheral blood T lymphocytes targeted to prostate-specific membrane antigen (PSMA), an antigen ex

219 We hypothesize that the prostate-specific membrane antigen (PSMA), an attractive

220 -617 is a radioligand with high affinity for prostate-specific membrane antigen (PSMA), enabling targ

221 Prostate-specific membrane antigen (PSMA), expressed by

222 Metastatic prostate carcinoma overexpresses prostate-specific membrane antigen (PSMA), making this a

223 radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen (PSMA), N-[N-[(S)-1,3

224 tanis et al. report a new signaling role for prostate-specific membrane antigen (PSMA), providing a m

225 (68)Ga-labeled urea-based inhibitors of the prostate-specific membrane antigen (PSMA), such as (68)G

226 (68)Ga-labeled urea-based inhibitors of the prostate-specific membrane antigen (PSMA), such as (68)G

227 elopment of new imaging agents targeting the prostate-specific membrane antigen (PSMA), we have used

228 x 10(6)) (RM1), transduced to express human prostate-specific membrane antigen (PSMA), were injected

229 (18)F-prostate-specific membrane antigen (PSMA)-1007 is excret

230 ad-to-head comparison between (68)Ga-labeled prostate-specific membrane antigen (PSMA)-11 and (18)F-f

231 was to estimate the effect of (68)Ga-labeled prostate-specific membrane antigen (PSMA)-11 PET on the

232 one metastases detected by total-body (68)Ga-prostate-specific membrane antigen (PSMA)-11 PET/CT and

233 eful lower limit of injected dose for (68)Ga-prostate-specific membrane antigen (PSMA)-11 PET/CT imag

234 (68)Ga-prostate-specific membrane antigen (PSMA)-11 PET/CT repr

235 A first analysis of simultaneous (68)Ga-prostate-specific membrane antigen (PSMA)-11 PET/MRI sho

236 tudy was to evaluate the efficacy of (177)Lu-prostate-specific membrane antigen (PSMA)-617 ((177)Lu-P

237 (177)Lu-prostate-specific membrane antigen (PSMA)-617 enables ta

238 ted and applied to the assessment of (177)Lu-prostate-specific membrane antigen (PSMA)-617 therapy fo

239 Our objective was to introduce (90)Y-labeled prostate-specific membrane antigen (PSMA)-617 to clinica

240 (18)F-PSMA-1007 is a novel prostate-specific membrane antigen (PSMA)-based radiopha

241 A library of new prostate-specific membrane antigen (PSMA)-binding ligand

242 Prostate-specific membrane antigen (PSMA)-binding tracer

243 rticle generator (225)Ac to selectively kill prostate-specific membrane antigen (PSMA)-expressing cel

244 tubule agent drug maytansinoid-1 directly to prostate-specific membrane antigen (PSMA)-expressing cel

245 stic pathway for prostate cancer management, prostate-specific membrane antigen (PSMA)-ligand PET has

246 (18)F-labeled prostate-specific membrane antigen (PSMA)-ligand PET has

247 Prostate-specific membrane antigen (PSMA)-ligand PET ima

248 Prostate-specific membrane antigen (PSMA)-ligand PET is

249 tration as the first drug for PET imaging of prostate-specific membrane antigen (PSMA)-positive lesio

250 tion-resistant prostate cancer patients with prostate-specific membrane antigen (PSMA)-positive tumor

251 theranostic method that allows prediction of prostate-specific membrane antigen (PSMA)-positive tumor

252 We developed prostate-specific membrane antigen (PSMA)-targeted low-m

253 Using a previously developed prostate-specific membrane antigen (PSMA)-targeted PDT a

254 ion detection rate of (18)F-DCFPyL PET/CT, a prostate-specific membrane antigen (PSMA)-targeted PET a

255 Prostate-specific membrane antigen (PSMA)-targeted PET i

256 The introduction of (18)F-labeled prostate-specific membrane antigen (PSMA)-targeted PET/C

257 Prostate-specific membrane antigen (PSMA)-targeted radio

258 ic castration-resistant prostate cancer with prostate-specific membrane antigen (PSMA)-targeted radio

259 The prostate-specific membrane antigen (PSMA)-targeted radio

260 Prostate-specific membrane antigen (PSMA)-targeted radio

261 PET imaging with the prostate-specific membrane antigen (PSMA)-targeted radio

262 neuroendocrine biomarkers on the efficacy of prostate-specific membrane antigen (PSMA)-targeted radio

263 currently being revolutionized by the use of prostate-specific membrane antigen (PSMA)-targeted radio

264 Prostate-specific membrane antigen (PSMA)-targeted radio

265 Prostate-specific membrane antigen (PSMA)-targeted radio

266 The development of novel prostate-specific membrane antigen (PSMA)-targeted radio

267 function as well as therapeutic efficacy of prostate-specific membrane antigen (PSMA)-targeted radio

268 Prostate-specific membrane antigen (PSMA)-targeting alph

269 Prostate-specific membrane antigen (PSMA)-targeting beta

270 The aim was to compare the prostate-specific membrane antigen (PSMA)-targeting char

271 Prostate-specific membrane antigen (PSMA)-targeting PET

272 er has been shown to improve tumor uptake of prostate-specific membrane antigen (PSMA)-targeting radi

273 -HBED-CC-a (68)Ga-conjugated ligand of human prostate-specific membrane antigen (PSMA)-to localize ca

274 nity murine monoclonal antibody specific for prostate-specific membrane antigen (PSMA).

275 g recurrent prostate cancer by targeting the prostate-specific membrane antigen (PSMA).

276 dies targeting downstream effectors, such as prostate-specific membrane antigen (PSMA).

277 olecular-weight radiotracer that targets the prostate-specific membrane antigen (PSMA).

278 directed against an extracellular domain of prostate-specific membrane antigen (PSMA).

279 xythiophene) (PEDOT) nanowires, that detects prostate-specific membrane antigen (PSMA).

280 ls overexpressing the known cancer biomarker prostate-specific membrane antigen (PSMA).

281 hemotherapeutic conjugate designed to target prostate-specific membrane antigen (PSMA).

282 promising PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA).

283 imaging and therapeutic agents targeting the prostate-specific membrane antigen (PSMA); these were am

284 (68)Ga-labeled prostate-specific membrane antigen (PSMA-11) PET/CT dete

285 xypeptidase II family, best characterized by prostate-specific membrane antigen (PSMA/NAALAD1).

286 Prostate-specific-membrane-antigen (PSMA) is a marker pr

287 (18)F-rhPSMA-7 (radiohybrid prostate-specific membrane antigen [PSMA]) is a novel li

288 in bone marrow and tumors for (177)-labeled prostate-specific membrane antigen [PSMA])).

289 oped tracer 2-methoxy-(18)F-DCFPyL ((18)F-JK-prostate-specific membrane antigen [PSMA]-7) has shown f

290 CT scans of 7 patients who underwent (177)Lu prostate-specific membrane antigen radioligand therapy w

291 Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are

292 Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are

293 simetry of a novel (18)F-labeled radiohybrid prostate-specific membrane antigen (rhPSMA) PET imaging

294 )Tc-MIP-1404), a small-molecule inhibitor of prostate-specific membrane antigen, shows high potential

295 he results of a prospective study evaluating prostate-specific membrane antigen-targeted (18)F-DCFPyL

296 clusion: In this prospective study using the prostate-specific membrane antigen-targeted PET agent (1

297 y recurrent prostate cancer were greater for prostate-specific membrane antigen-targeted radiotracers

298 conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RP

299 amino]-pentyl}-ureido)-pentanedioic acid), a prostate-specific membrane antigen-targeting radiotracer

300 phosphoramidate peptidomimetic inhibitors of prostate-specific membrane antigen was determined by inh